治疗前FDG PET在肺淋巴上皮瘤样癌中的预后价值与临床影响
该回顾性研究纳入71例肺淋巴上皮瘤样癌(LELC)患者,其中41例治疗前接受FDG PET分期。多因素分析显示分期与治疗前FDG PET是总生存(OS)的独立预测因素,PET分期者5年OS率85.4%高于未PET者49.7%(P=0.012)。FDG PET使28.6%的CT定义III-IVA期患者分期上调,其中14.3%上调至IVB期。
要点
- 治疗前FDG PET与分期均为肺LELC总生存的独立预测因素。
- PET分期者5年OS率85.4%,未PET者49.7%(P=0.012)。
- FDG PET使28.6%的CT定义III-IVA期患者分期上调,14.3%升至IVB期。
核心结论
- 美国癌症联合委员会第八版分期与治疗前FDG PET是肺LELC患者总生存的独立预后因素。
- FDG PET改善疾病分期并优化治疗干预,最终改善生存结局。
研究设计与样本
- 回顾性临床记录审查纳入71例肺淋巴上皮瘤样癌患者,其中41例治疗前接受FDG PET进行原发分期。
- 采用Kaplan-Meier法与Cox回归模型(前向逐步选择)评估结局,分期变化为主要结局指标,所有患者按AJCC第八版重新分期。
主要发现
- 多因素分析显示分期与治疗前FDG PET为总生存的显著独立预测因素。
- I-II期、III-IVA期、IVB期患者的5年OS率分别为92.3%、70.4%、20.0%。
- FDG PET用于分期与更好的OS相关(P=0.003),PET分期与未PET分期者5年OS率分别为85.4%与49.7%(P=0.012)。
- FDG PET使28.6%的CT定义III-IVA期患者疾病分期上调,其中14.3%上调至IVB期。
关键数值与推荐
- I-II期5年OS率92.3%,III-IVA期70.4%,IVB期20.0%。
- PET分期者5年OS率85.4%,未PET者49.7%(P=0.012)。
- FDG PET使28.6%的CT定义III-IVA期患者分期上调,14.3%上调至IVB期。
临床怎么用
- 肺LELC患者治疗前应行FDG PET以完善分期并识别远处转移。
- FDG PET分期结果可用于优化治疗干预决策。
局限性
- 回顾性研究设计,样本量71例,其中仅41例接受FDG PET分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Compared with other forms of non-small cell lung cancer, pulmonary lymphoepithelioma-like carcinoma (LELC) is rarer and portends better outcomes. We sought to investigate the prognostic role and clinical impact of pretreatment F-FDG PET in pulmonary LELC. METHODS: A total of 71 patients with pulmonary LELC were identified through a retrospective review of clinical records. Of them, 41 underwent F-FDG PET for primary staging. Outcomes were assessed using the Kaplan-Meier method and Cox regression models with a forward stepwise selection procedure. Staging changes served as the main outcome measure for assessing the impact of F-FDG PET. For the purpose of analyses, all patients were restaged according the American Joint Committee on Cancer Staging Manual eighth edition. RESULTS: Stage and pretreatment F-FDG PET were significantly independent predictors of overall survival (OS) on multivariate analysis. Five-year OS rates for patients with stages I-II, III-IVA, and IVB were 92.3%, 70.4%, and 20.0%, respectively. The use of F-FDG PET for staging purposes was associated with a better OS (P = 0.003). Specifically, the 5-year OS rates for patients who were staged with and without F-FDG PET were 85.4% and 49.7%, respectively (P = 0.012). F-FDG PET resulted in a disease upstage in 28.6% of patients with CT-defined stages III-IVA; of them, 14.3% were upstaged to IVB disease. CONCLUSIONS: The American Joint Committee on Cancer eighth edition stage and pretreatment F-FDG PET were independent prognostic factors for OS in patients with pulmonary LELC. F-FDG PET imaging resulted in a better disease staging with a corresponding optimization of therapeutic interventions, which ultimately improved survival outcomes.
引用
- Su TP, Ho KC, Wang CW, et al. Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma. Clin Nucl Med. 2019. PMID: 30608914. doi:10.1097/RLU.0000000000002371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。